Skip to Content

ULTRA Fel-O-Vax FVRCP + FeLV

This page contains information on ULTRA Fel-O-Vax FVRCP + FeLV for veterinary use.
The information provided typically includes the following:
  • ULTRA Fel-O-Vax FVRCP + FeLV Indications
  • Warnings and cautions for ULTRA Fel-O-Vax FVRCP + FeLV
  • Direction and dosage information for ULTRA Fel-O-Vax FVRCP + FeLV

ULTRA Fel-O-Vax FVRCP + FeLV

This treatment applies to the following species:
Company: Elanco US

Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Vaccine

Killed Virus

For use in animals only

This product has been shown to be effective for vaccination of healthy cats 8 weeks of age or older against feline leukemia, rhinotracheitis, calici, and panleukopenia viruses. The duration of immunity for this product has not been determined. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.

The vaccine contains one additional feline calicivirus strain isolated from one hemorrhagic calicivirus outbreak that occurred in 1998 and was shown to be effective in vaccinated cats against calicivirus-induced hemorrhagic disease in controlled vaccination challenge experiments.

Dose: Inject one 0.5 mL dose subcutaneously using aseptic technique. Healthy cats should receive two doses, 3 to 4 weeks apart, except that if the animal is less than 16 weeks of age, the final dose should be given no earlier than 16 weeks of age. The presence of maternal antibody is known to interfere with the development of active immunity in cats and additional boosters will be required in most young animals. Historically, annual revaccination with a single dose has been recommended for this product.The need for this booster has not been established. For advice on revaccination frequency and annual booster vaccinations, consultation with a veterinarian is recommended.

ULTRA Fel-O-Vax FVRCP + FeLV Caution

Store in the dark at 2° to 8°C (35° to 46°F). AVOID FREEZING. SHAKE WELL. Do not mix with other products, except as specified on the label. This product has not been tested in pregnant animals. A small percentage of patients may experience transient lethargy, pyrexia and anorexia, and some cats may show transient discomfort (such as stinging, itching or pain) at the injection site. In exceptional circumstances, hypersensitivity or anaphylaxis may occur, requiring appropriate symptomatic treatment. In case of human exposure, contact a physician.

Thimerosal, neomycin, polymyxin B and amphotericin B added as preservatives.

ULTRA Fel-O-Vax FVRCP + FeLV Caution

In the absence of a veterinarian-client-patient relationship, Federal law prohibits the relabeling, repackaging, resale, or redistribution of the individual contents of this package.

ULTRA, Fel-O-Vax, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

© 2017 Elanco US Inc. all rights reserved.

Elanco US Inc., Fort Dodge, IA 50501

Phone: 888-545-5973

VLN/PCN 196/15B5.22

25 Doses/25 x 0.5 mL Vials of Vaccine

YL101682X

CPN: 1943026.1

ELANCO US INC.
FORT DODGE, IA, 50501
Customer Service:   317-276-1262
Technical Service:   800-428-4441
Website:   www.elanco.us
Email:   elanco@elanco.com
Every effort has been made to ensure the accuracy of the ULTRA Fel-O-Vax FVRCP + FeLV information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2019 Animalytix LLC. Updated: 2019-09-30

Hide